~~What is claimed is:~~Claims:

1. A hydrogel ocular insert that is placed into the conjunctival sac of an eye when being used by a patient and is made of~~,~~ ~~comprising~~ a hydrogel material,

wherein the hydrogel ocular insert is stored in a packaging aqueous solution in a sealed and sterilized package, wherein the packaging aqueous solution has a pH of from 7.5 to 9.0, wherein the hydrogel ocular insert has an on-eye dissolution time of from 4 to 24 hours,

wherein the hydrogel ocular insert has a shape of a rod, a sphere, an oval, a ring, a square, a rectangle, a triangle, or an irregular shape and a thickness of from 50 to 400 μm, wherein the shape of the hydrogel ocular insert has a maximum size of 5-6 mm in any single dimension,

wherein the hydrogel material is a crosslinked polymeric material which is a crosslinking product of at least one arylborono-containing hydrophilic copolymer ~~including arylborono-containing repeating units each having an arylborono group~~ and at least one mucoadhesive polymer including repeating units each having a moiety selected from the group consisting of 1,2-diol moiety, 1,3-diol moiety, α-hydroxycarboxylic acid moiety, and β-hydroxycarboxylic acid moiety,


wherein said at least one arylborono-containing hydrophilic copolymer comprises (a) from 2% to 18% by mole of the arylborono-containing repeating units, (b) from 70% to 95% by mole of repeating units of at least one phosphorylcholine-containing vinylic monomer, and (c) from 3% to 15% by mole of acrylic monomeric units of at least one acrylic monomer having 3 to 16 carbon atoms, provided that the sum of the mole percentages of components (a), (b) and (c) and other components not listed above is 100%,

wherein said at least one mucoadhesive polymer is present in an amount of from 70% to 98% by weight relative to the dry weight of the hydrogel ocular insert,

wherein said at least one arylborono-containing hydrophilic copolymer and said at least one mucoadhesive polymer are crosslinked in the crosslinked polymeric material through crosslinks each formed between one of arylborono groups of said at least one arylborono-containing hydrophilic copolymer and one 1,2-diol, 1,3-diol, α-hydroxycarboxylic acid, or β-hydroxycarboxylic acid moiety of said at least one mucoadhesive polymer.




2. The hydrogel ocular insert of claim 1, ~~wherein said at least one arylborono-containing hydrophilic copolymer comprises an arylborono-containing vinyl-based copolymer comprising (a) arylborono-containing repeating units of at least one arylborono-containing vinylic monomer and (b) hydrophilic repeating units of at least one hydrophilic vinylic monomer.~~






~~3. The hydrogel ocular insert of claim 2,~~ wherein said at least one arylborono-containing vinylic monomer is represented by formula (II)










(II)

in which: ~~$R_1$ is a monovalent radical (preferably~~ $R_1$ is H, $NO_2$, F, Cl, Br, $CF_3$, $CH_2OH$, or $CH_2NR^oR^{o'}$~~)~~;

Q is a monovalent radical of , , ,

, , , , or ;

L is a direct bond, a $C_1$-$C_4$ alkylene divalent radical, a divalent radical of ,

, , , , , , or  in which $Y_1$ is CH(OH) or a $C_1$-$C_4$ alkylene divalent radical, $Y_2$ is a $C_1$-$C_4$ alkylene divalent radical, p1 is an integer of 0 to 3, and $R^o$ is H or a $C_1$-$C_4$ alkyl.

~~4~~3. The hydrogel ocular insert of ~~any one of~~ claim~~s~~ 2 ~~or 3~~, wherein said at least one arylborono-containing vinylic monomer is selected from the group consisting of 3-vinylphenylboronic acid, 4-vinylphenylboronic acid, 3-(meth)acrylamidophenylboronic acid, 4-(meth)acrylamidophenylboronic acid, 3-(meth)acrylamido-5-nitrophenylboronic acid, 4-(meth)acrylamido-5-nitrophenylboronic acid, 4-(meth)acrylamido-3-nitrophenylboronic acid, 3-[(meth)acrylamido-$C_2$-$C_5$-alkylaminocarbonyl]-5-nitrophenylboronic acid, 3-[(meth)acryloyloxy-$C_2$-$C_5$-alkylaminocarbonyl]-5-nitrophenylboronic acid, 3-(meth)acrylamido-6-hydroxymethylphenylboronic acid, 3-(meth)acrylamido-6-dimethylaminomethylphenylboronic acid, 4-(meth)acrylamido-6-hydroxymethylphenylboronic acid, 4-(meth)acrylamido-6-dimethylaminomethylphenyl-boronic acid, 4-(1,6-Dioxo-2,5-diaza-7-oxamyl)phenylboronic acid, 4-(N-allylsulfamoyl)phenylboronic acid, 4-(3-butenylsulfonyl)phenylboronic acid, a reaction production of an amino-containing phenylboronic acid derivative with (meth)acrylic acid halide, a reaction product of an amino-containing phenylboronic acid derivative with a carboxy-containing vinylic monomer in the presence of a carbodiimide and N-hydroxysuccinimide, a reaction production of a carboxy-containing phenylboronic acid derivative with an amino-containing vinylic monomer in the presence of a carbodiimide and N-hydroxysuccinimide, and combinations thereof, wherein the carboxy-containing phenylboronic acid derivative is selected from the group consisting of 3-carboxyphenylboronic acid, 4-carboxyphenylboronic acid, 3-boronophenylacetic acid, 4-boronophenylacetic acid, 2-(4-boronophenyl)-2-methylpropanoic acid, 3-(4-

boronophenyl)propanoic acid, 3-(3-boronophenyl)propanoic acid, 5-(3-boronophenyl)-pentanoic acid, 5-(4-boronophenyl)pentanoic acid, 4-(2-carboxyethyl)-3-nitrophenylboronic acid, 3-carboxy-5-nitrophenylboronic acid, 4-carboxy-3-chlorophenylboronic acid, 3-carboxy-4-fluorophenylbornic acid, 3-(3-carboxypropyonylamino)phenylboronic acid, 3-amino-3-(4-boronophenyl)propanoic acid, and combinations thereof,

wherein the amino-containing phenylboronic acid derivative is selected from the group consisting of 3-aminophenylboronic acid, 4-aminophenylboronic acid, 4-amino-3-nitrophenylboronic acid, 3-amino-6-hydroxymethylphenylboronic acid, 3-amino-6-(dimethylaminomethyl)phenylboronic acid, 4-amino-2-hydroxymethylphenylboronic acid, 4-amino-2-(dimethylaminomethyl)phenylboronic acid, 3-amino-4-fluorophenylboronic acid, 4-(aminomethyl)-5-nitrophenylboronic acid, 3-(aminomethyl)-phenylboronic acid, 3-amino-5-nitrophenylboronic acid, 3-amino-3-(4-boronophenyl)propanoic acid, and combinations thereof,

wherein the carboxyl-containing vinylic monomer is selected from the group consisting of 2-acrylamidoglycolic acid, 3-acrylamidopropionic acid, 4-acrylamidobutanoic acid, 5-acrylamidopentanoic acid, 3-acryloyloxypropanoic acid, 4-acryloyloxybutanoic acid, 5-acryloyloxypentanoic acid, and combinations thereof,

wherein the amino-containing vinylic monomers is selected from the group consisting of amino–$C_2$-$C_4$ alkyl (meth)acrylate, $C_1$-$C_3$ alkylamino–$C_2$-$C_4$ alkyl (meth)acrylate, amino–$C_2$-$C_4$ alkyl (meth)acrylamide, $C_1$-$C_3$ alkylamino–$C_2$-$C_4$ alkyl (meth)acrylamide, vinylamine, allylamine, and combinations thereof.

54. The hydrogel ocular insert of any one of claims 1 to 43, ~~wherein said at least one arylborono-containing hydrophilic copolymer comprises (a) from about 0.1% to about 25% by mole of the arylborono-containing repeating units, (b) from about 55% to about 98.9% by mole of repeating units of at least one phosphorylcholine-containing vinylic monomer, and (c) from about 1% by mole to about 20% by mole of acrylic monomeric units of at least one acrylic monomer having 3 to 16 carbon atoms, provided that the sum of the mole percentages of components (a), (b) and (c) and other components not listed above is 100%.~~

~~6. The hydrogel ocular insert of claim 5,~~ wherein said at least one acrylic monomer is selected from the group consisting of a $C_1$–$C_{12}$ alkyl (meth)acrylate, a hydroxy-substituted $C_2$–$C_{12}$ alkyl (meth)acrylate, a carboxy-substituted $C_2$–$C_{12}$ alkyl (meth)acrylate, an $NH_2$-substituted $C_2$–$C_{12}$ alkyl (meth)acrylate, a methylamino-substituted $C_2$–$C_{12}$ alkyl (meth)acrylate, a dimethylamino-substituted $C_2$–$C_{12}$ alkyl (meth)acrylate, an ethylamino-substituted $C_2$–$C_{10}$ alkyl (meth)acrylate, a diethylamino-substituted $C_2$–$C_8$ alkyl (meth)acrylate, a $C_2$–$C_{12}$ alkyl (meth)acrylamide, a hydroxy-substituted $C_2$–$C_{12}$ alkyl (meth)acrylamide, a carboxy-substituted $C_2$–$C_{12}$ alkyl

(meth)acrylaide, an $NH_2$-substituted $C_2$–$C_{12}$ alkyl (meth)acrylamide, a methylamino-substituted $C_2$–$C_{12}$ alkyl (meth)acrylamide, a dimethylamino-substituted $C_2$–$C_{12}$ alkyl (meth)acrylamide, an ethylamino-substituted $C_2$–$C_{10}$ alkyl (meth)acrylamide, a diethylamino-substituted $C_2$–$C_8$ alkyl (meth)acrylamide, ethylene glycol (meth)acrylate, di(ethylene glycol) (meth)acrylate, tri(ethylene glycol) (meth)acrylate, tetra(ethylene glycol) (meth)acrylate, ethylene glycol methyl ether (meth)acrylate, di(ethylene glycol) methyl ether (meth)acrylate, tri(ethylene glycol) methyl ether (meth)acrylate, tetra(ethylene glycol) methyl ether (meth)acrylate, and combinations thereof, wherein the phosphorylcholine-containing vinylic monomer is selected from the group consisting of (meth)acryloylox-yethyl phosphorylcholine, (meth)acryloyloxypropyl phosphorylcholine, 4-((meth)acryloyloxy)butyl-2'-(trimethylammonio)ethylphosphate, 2-[(meth)acryloylamino] ethyl-2'-(trimethylammonio)-ethylphosphate, 3-[(meth)acryloyl-amino]propyl-2'-(trimethylammonio)ethylphosphate, 4-[(meth)acryloylamino]butyl-2'-(trimethylammonio) ethylphosphate, 5-((meth)acryloyloxy)pentyl-2'-(trimethylammonio)ethyl phosphate, 6-((meth)acryloyloxy)hexyl-2'-(trimethylammonio)-ethylphosphate, 2-((meth)acryloyloxy) ethyl-2'-(triethylammonio)ethylphosphate, 2-((meth)acryloyloxy)ethyl-2'-(tripropylammonio)ethylphosphate, 2-((meth)acryloyloxy)ethyl-2'-(tributylammonio)ethyl phosphate, 2-((meth)acryloyloxy)propyl-2'-(trimethylammonio)-ethylphosphate, 2-((meth)acryloyloxy)butyl-2'-(trimethylammonio)ethylphosphate, 2-((meth)acryloyloxy) pentyl-2'-(trimethylammonio)ethylphosphate, 2-((meth)acryloyloxy)hexyl-2'-(trimethyl-ammonio)ethyl phosphate, 2-(vinyloxy)ethyl-2'-(trimethylammonio)ethyl-phosphate, 2-(allyloxy)ethyl-2'-(trimethylammonio)ethylphosphate, 2-(vinyloxycarbonyl) ethyl-2'-(trimethylammonio)ethyl phosphate, 2-(allyloxycarbonyl)ethyl-2'-(trimethylammonio)-ethylphosphate, 2-(vinylcarbonylamino)ethyl-2'-(trimethylammonio) ethylphosphate, 2-(allyloxycarbonylamino)ethyl-2'-(trimethylammonio)ethyl phosphate, 2-(butenoyloxy)ethyl-2'-(trimethylammonio)ethylphosphate, and combinations thereof.

~~7~~5. The hydrogel ocular insert of claim ~~5~~4, wherein said at least one acrylic monomer is n-butyl (meth)acrylate and/or di(ethylene glycol) methyl ether (meth)acrylate.

~~8. The hydrogel ocular insert of any one of claims 5 to 7, wherein the phosphorylcholine-containing vinylic monomer is selected from the group consisting of (meth)acryloylox-yethyl phosphorylcholine, (meth)acryloyloxypropyl phosphorylcholine, 4-((meth)acryloyloxy)butyl-2'-(trimethylammonio)ethylphosphate, 2-[(meth)acryloylamino] ethyl-2'-(trimethylammonio)-ethylphosphate, 3-[(meth)acryloylamino]propyl-2'-(trimethylammonio)ethylphosphate, 4-[(meth)acryloylamino]butyl-2'-(trimethylammonio) ethylphosphate, 5-((meth)acryloyloxy)pentyl-2'-(trimethylammonio)ethyl phosphate, 6-((meth)acryloyloxy)hexyl-2'-(trimethylammonio)-ethylphosphate, 2-((meth)acryloyloxy)~~

ethyl-2'-(triethylammonio)ethylphosphate, 2-((meth)acryloyloxy)ethyl-2'-(tripropylammonio)ethylphosphate, 2-((meth)acryloyloxy)ethyl-2'-(tributylammonio)ethyl phosphate, 2-((meth)acryloyloxy)propyl-2'-(trimethylammonio)-ethylphosphate, 2-((meth)acryloyloxy)butyl-2'-(trimethylammonio)ethylphosphate, 2-((meth)acryloyloxy) pentyl-2'-(trimethylammonio)ethylphosphate, 2-((meth)acryloyloxy)hexyl-2'-(trimethylammonio)ethyl phosphate, 2-(vinyloxy)ethyl-2'-(trimethylammonio)ethyl-phosphate, 2-(allyloxy)ethyl-2'-(trimethylammonio)ethylphosphate, 2-(vinyloxycarbonyl) ethyl-2'-(trimethylammonio)ethyl phosphate, 2-(allyloxycarbonyl)ethyl-2'-(trimethylammonio)ethylphosphate, 2-(vinylcarbonylamino)ethyl-2'-(trimethylammonio) ethylphosphate, 2-(allyloxycarbonylamino)ethyl-2'-(trimethylammonio)ethyl phosphate, 2-(butenoyloxy)ethyl-2'-(trimethylammonio)ethylphosphate, and combinations thereof.

9. The hydrogel ocular insert of any one of claims 1 to 4, wherein the arylborono-containing hydrophilic copolymer comprises (a) from about 0.1% by mole to about 25% by mole of the arylborono-containing repeating units and (b) from about 75% by mole to about 99.9% by mole of repeating units of at least one hydrophilic vinylic monomer, provided that the sum of the mole percentages of components (a) and (b) and other components not listed above is 100%.

106. The hydrogel ocular insert of any one of claims 1 to 95, wherein the arylborono groups independent of one another have a pKa of from 7.2 to 9.0 about 6.8 to 9.2, wherein said at least one arylborono-containing hydrophilic copolymer has a number average molecular weight of from about 5,000 Daltons to 500,000 Daltons.

117. The hydrogel ocular insert of any one of claims 1 to 106, wherein said at least one mucoadhesive polymer comprises a galactomannan polymer, dextran, mannan, hyaluronic acid, polyvinyl alcohol.

128. The hydrogel ocular insert of any one of claims 1 to 106, wherein said at least one mucoadhesive polymer comprises a guar and/or a chemically-modified galactomannan selected from the group consisting of Hydroxyethyl guar, hydroxypropyl guar, methyl guar, ethyl guar, propyl guar, carboxymethyl guar, carboxymethylhydroxypropyl guar, hydroxypropyltrimonium chloride guar, and combinations thereof.

139. The hydrogel ocular insert of any one of claims 1 to 128, wherein said at least one mucoadhesive polymer is present in an amount of from 80% to 98% about 50 % to about 99% by weight relative to the dry weight of the hydrogel ocular insert.

14110.The hydrogel ocular insert of any one of claims 1 to 139, wherein the hydrogel ocular insert is hydrolytically stable in an aqueous solution at a pH of from about 7.5 to 9.5 and has an equilibrium water content of from about 10% to about 70% by weight (at room temperature, about 22ºC to 28ºC), when being fully hydrated.

15. The hydrogel ocular insert of any one of claims 1 to 14, wherein the hydrogel ocular

~~insert has a shape having a maximum size in any single dimension of 5-6 mm.~~

~~16. The hydrogel ocular insert of claim 15, wherein the hydrogel ocular insert has a shape of a rod, a sphere, an oval, a ring, a square, a rectangle, a triangle, or an irregular shape.~~

~~17. The hydrogel ocular insert of any one of claims 1 to 16, wherein the hydrogel ocular insert has a thickness of about 50 to about 400 μm.~~

~~18. The hydrogel ocular insert of any one of claims 1 to 17, wherein the hydrogel ocular insert has an on-eye dissolution time of at least 3 hours.~~

~~19~~11. The hydrogel ocular insert of any one of claims 1 to ~~18~~10, wherein the hydrogel ocular insert has a layered structure and comprises a first hydrogel layer sandwiched between two second hydrogel layers, wherein the first hydrogel layer has a first crosslinking density of first crosslinks and the second hydrogel layers have a second crosslinking density of second crosslinks, wherein the first crosslinking density is higher than the second crosslinking density and/or the first crosslinks hydrolyze more slowly than the second crosslinks in the tear of the eye.

~~20~~12. The hydrogel ocular insert of any one of claims 1 to ~~19~~11, wherein the hydrogel ocular insert comprises one or more additional pharmaceutical active agents.

~~21~~13. The hydrogel ocular insert of claim ~~20~~12, wherein said one or more additional pharmaceutical active agents are selected from the group consisting of ocular lubricants, anti-redness relievers ~~(such as brimonidine tartrate, tetrahydrozoline, naphazoline)~~, cooling agents ~~(such as menthol)~~, steroids and nonsteroidal anti-inflammatory agents to relieve ocular pain and inflammation, antibiotics, anti-histamines ~~(such as olopatadine)~~, anti-virals, antibiotics and anti-bacterials for infectious conjunctivitis, anti-muscarinics ~~(such as atropine and derivatives thereof)~~ for myopia treatment, and glaucoma drug~~s delivery (such as prostaglandin and prostaglandin analogs such as travoprost)~~, and therapeutically suitable combinations thereof.

~~22. The hydrogel ocular insert of any one of claims 1 to 21, wherein the hydrogel ocular insert is stored in a packaging aqueous solution in a sealed and sterilized package, wherein the packaging aqueous solution has a pH of from about 7.5 to about 9.0 and a tonicity of from about 200 to about 450 milliosmol (mOsm).~~

~~23. A method for producing a hydrogel ocular insert of any one of claims 1 to 22, comprising the step of: curing a reactive composition to form a hydrogel which is in a form of the ocular insert or is machined into the form of the ocular insert, wherein the reactive composition comprises said at least one arylborono-containing hydrophilic copolymer and said at least one mucoadhesive polymer both dissolved in a solvent.~~

14. The hydrogel ocular insert of claim 13, wherein the anti-redness relievers are brimonidine tartrate, tetrahydrozoline, naphazoline, wherein the cooling agents are menthol, wherein the anti-histamines are olopatadine, wherein the anti-muscarinics are atropine and

derivatives thereof, wherein the glaucoma drugs are prostaglandin and prostaglandin analogs.